hope_my_calls_print
Posted - 1 week ago
$IMVT 28s a pretty attractive entry point for LEAPs, right? Seems to be a lot of support down around 25 and we have a shitload of catalysts coming up. Am I missing anything?
Quantumup
Posted - 1 week ago
Stifel⬆️PT $VRDN $41 was $40/Buy, after +VE THRIVE-1 P3🔬from back in Sept—remains confident in the prospects of upcoming THRIVE-2 P3🔬— in its base case of comparable efficacy2 Tepezza, thinks shrs could see 10%-20%⬆️— potential⬇️side is significant in Re to filing next year: $amgn $imvt
NVDAMillionaire
Posted - 1 week ago
$IMVT Immunovant, Inc. (NASDAQ:IMVT): Driving Autoimmune Breakthroughs with a Promising Pipeline https://beyondspx.com/article/immunovant-inc-nasdaq-imvt-driving-autoimmune-breakthroughs-with-a-promising-pipeline
insiderbuyingselling
Posted - 10/25/24
$IMVT new insider selling: 2740 shares. http://insiderbuyingselling.com/?t=IMVT
insiderbuyingselling
Posted - 1 month ago
$IMVT new insider selling: 3271 shares. http://insiderbuyingselling.com/?t=IMVT
Quantumup
Posted - 1 month ago
H.C. Wainwright reiterated $MLTX Buy/$100, after conducting a survey of high-prescribing psoriatic arthritis (PSA) MD's to gain an understanding of how emerging IL-17 inhibitors could change existing Tx paradigms for patients with PsA. HCW🔑takeaways: $ucbjy $imvt $slrn $abbv nvs
swingingtech
Posted - 1 month ago
$IMVT $ALB $GCT
https://wallstreetwaves.com/significant-friday-options-movements-imvt-alb-gct/
insiderbuyingselling
Posted - 1 month ago
$IMVT new insider selling: 5162 shares. http://insiderbuyingselling.com/?t=IMVT
IN0V8
Posted - 1 month ago
$IMVT Opportunity Oppenheimer raises target price to $53 from $47
Quantumup
Posted - 1 month ago
Oppenheimer⬆️ $IMVT $53 was $47/OP OPY revises its model2 include Graves (of which TED represents a subset), where they project risk-unadj🇺🇸sales of $1.3B in '32 based on incidence rates—sees upside pot on uptake into the much larger prevalence population: $vrdn $amgn $argx $bhvn
brs555
Posted - 1 month ago
$ABUS $IMVT Same story. Same outcome..
StockInvest_us
Posted - 09/26/24
Signal alert: $IMVT - Oversold Trend Short (Undervalued) https://stockinvest.us/l/h0hHS3igLz
ShareholderIncentives
Posted - 2 months ago
$ROIV $ABUS Still reading lots of speculation about Roivant using their $6B cash to purchase the remainder of $ABUS.
I do not see it happening. First, $ROIV has repeatedly said at multiple conferences that they have zero intention of using a large potion of their cash for a deal to acquire anyone. They’re stingy. Second, they just sold Dermavant to offload debt. Third, even if they were to use cash, many others think Roivant would be much more interested in acquiring the remainder of $IMVT.
All of this is not to say that no deal will ever be made with $ABUS - just that any deal involving Roivant will unlikely involve much cash from them.
DonCorleone77
Posted - 2 months ago
$ROIV $OGN $IMVT Roivant disposal deal good for sentiment and cash burn, says Jefferies After Organon (OGN) announced an agreement to acquire Dermavant, a Roivant (ROIV) company, for "up to" $1.2B, Jefferies said "upon closer look it's actually $175M upfront" plus a $75M payment on AD approval, expected in Q4 2024, and $950M in commercial milestones that are spread out over time. However, "importantly," this removes $200M-plus a year in OpEx spend that Roivant books on its profit/loss statement, which should more than accommodate the significant uptick in R&D spend for Immunovant's (IMVT) pivotal programs and the firm calls "more important to us than upfront economics." The firm, which calls the Dermavant disposal "good for overall sentiment and cash burn," has a Buy rating and $18 price target on Roivant shares.
brs555
Posted - 2 months ago
Same story as $IMVT In Matt we trust..
Quantumup
Posted - 2 months ago
Goldman Sachs⬆️PT $VRDN $31 was $25/Buy~views the overall topline results paint a differentiated profile that's pot'ly superior2 Tepezza's ( $AMGN ) w/ substantive comm advantages that goes beyond just a shorter 5-dose regimen; believes results partially de-risked THRIVE-2/VRDN-003: $imvt
brs555
Posted - 2 months ago
Price action reminds me of $IMVT 2 years ago.
RoyMunson69
Posted - 2 months ago
$IMVT Pile o shit
Quantumup
Posted - 2 months ago
BTIG⬆️PT $VRDN $56 was $46/Buy +⬆️the PoS for veligrotug in active/chronic TED=90%/80%/⬆️the peak penetration in active TED to 30% was 20%, after the Tx showed comparable proptosis efficacy vs $AMGN's Tepezza, w/ AEs looking BiC and also a less burdensome infusion regimen (5 vs. 8): $imvt
IN0V8
Posted - 2 months ago
$IMVT Opportunity Citigroup raises target price to $60 from $51
Quantumup
Posted - 2 months ago
Citi⬆️ $IMVT $60 was $51/Buy: Stifel reit'd $IMVT Buy/$52: Oppenheimer reit'd $IMVT Outperform/$47: Goldman Sachs reit'd $IMVT Buy/$50: BofA reit $IMVT Buy/$49⬆️Graves" PoS=65% +updated rev/EPS model: 2026 rev=$394.3M (-$1.07 EPS) 2027 rev=$1,153.7B (+$2.51 EPS): $roiv $argx
hope_my_calls_print
Posted - 2 months ago
$IMVT data looks good IMO, but market pretty unimpressed it seems.
RonIsWrong
Posted - 2 months ago
$IMVT Immunovant(IMVT) said on Monday that high doses of its experimental drug batoclimab to treat Graves' Disease significantly reduced IgG levels and improved patient responses compared to lower doses in a phase 2 study. The study showed that a 680 mg weekly dose led to a 77% reduction in IgG and a 76% response rate, while the 340 mg dose resulted in a 65% IgG reduction and a 68% response rate. The company plans to commence a pivotal trial of IMVT-1402 in Graves' Disease by December 31, following the U.S. Food & Drug Administration alignment and Investigational New Drug Application clearance.
thetechtrader
Posted - 2 months ago
$IMVT tagged +1.25, popped 1.90 to near 36, then tagged 35.50. Extension targets are 37.50 & 39 Support 34.35-40. #stockstowatch #daytrading #swingtrading #daytrader #stockmarket #technicalanalysis #harryboxer #priceaction #smartmoney #chartanalysis #swingtrading #swingtrade #daytrade #daytrading #tradingtips #investing #thetechtrader #marketnews #marketanalysis
DonCorleone77
Posted - 2 months ago
$ROIV $IMVT Roivant Sciences provides update on Graves' Disease development program Immunovant reported results from the Phase 2a trial of batoclimab in Graves' Disease. Immunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD treated patients who are intolerant to, uncontrolled on or relapsed after ATDs. Finally, Immunovant also announced alignment with the U.S. Food & Drug Administration and Investigational New Drug Application clearance with initiation of a pivotal trial of IMVT-1402 in GD expected by December 31, 2024. As previously disclosed, the batoclimab phase 2a trial in uncontrolled GD enrolled patients who were hyperthyroid despite ATD therapy. Participants in the trial received 12 weeks of high dose batoclimab, 680 mg weekly by subcutaneous injection followed by 12 weeks of lower dose batoclimab, 340 mg weekly SC. At the end of the first 12 weeks, participants experienced a mean IgG reduction of 77% leading to a 76% Response rate. In addition, by the end of 12 weeks of higher dose batoclimab, 56% achieved an ATD-Free Response. Despite benefiting from a lower starting IgG level after 12 weeks of 680mg therapy, during Weeks 13 to 24, the lower 340mg dose of batoclimab resulted in mean IgG reduction of 65% with a correspondingly lower responder rate of 68%. In addition, a lower ATD-Free Response rate of 36% was also observed in the second 12 weeks. Finally, patients who achieved at least a 70% IgG reduction at the end of the trial had nearly a threefold higher ATD-Free Response rate than those who did not.
